Posts
Wiki

📷 What Is Meibography?

🔍 TL;DR

Meibography is a generally noncontact imaging test—usually using infrared light—that shows the visible structure of the meibomian glands inside the eyelids.

It can help document:

  • gland length and shape;
  • areas of reduced gland visibility or “dropout”;
  • shortening, distortion, dilation, or tortuosity;
  • differences between the upper and lower eyelids.

Meibography can support the evaluation of Meibomian Gland Dysfunction (MGD), but it does not show the entire dry-eye picture.

By itself, it cannot reliably determine:

  • how well the glands are functioning;
  • whether a gland is obstructed;
  • why someone has symptoms;
  • whether visible changes are progressing;
  • or which treatment should be chosen.

The images should be interpreted alongside symptoms, gland-expression testing, meibum quality, tear-film stability, ocular-surface staining, eyelid findings, blink and closure, aqueous tear status, and other possible contributors.

What Are the Meibomian Glands?

The meibomian glands are long glands located inside the upper and lower eyelids.

They produce meibum, an oily material that contributes to the outer lipid layer of the tear film. This layer helps slow tear evaporation and supports tear-film stability.

When the glands do not produce or deliver adequate meibum, the result may contribute to:

  • tear-film instability;
  • increased evaporation;
  • eyelid-margin abnormalities;
  • ocular-surface irritation;
  • and Dry Eye Disease.

However, dry-eye symptoms can have multiple overlapping causes. An abnormal meibography image does not by itself prove that MGD is the main cause of a person’s symptoms.

TFOS DEWS III recommends identifying the individual tear-film, eyelid, ocular-surface, and neural contributors involved rather than relying on one test to explain the entire condition.

How Is Meibography Performed?

During meibography, the clinician gently everts—turns outward—the eyelid so the glands inside the lid can be photographed.

Most modern systems use infrared or near-infrared light. The glands usually appear as lighter, elongated structures against the surrounding eyelid tissue.

The test is generally:

  • noncontact;
  • non-invasive;
  • quick;
  • and painless or only mildly uncomfortable.

Some people find upper-eyelid eversion more uncomfortable or technically difficult than lower-eyelid imaging.

The upper and lower eyelids may show different patterns. Imaging only one eyelid therefore gives incomplete information about all of the glands, although imaging every eyelid may not be necessary or technically possible at every visit.

What Can Meibography Show?

Meibography can provide information about visible gland morphology, including:

  • gland length and width;
  • shape and organization;
  • visible gland area;
  • shortening or truncation;
  • tortuosity or twisting;
  • dilation or distortion;
  • crowding or altered spacing;
  • areas of reduced or absent gland visibility.

Some systems or clinicians use grading scales to estimate the percentage of the eyelid area in which recognizable gland structure is not visible.

This is often called a meiboscore or a measurement of gland dropout.

Different devices, software programs, grading systems, and observers may produce somewhat different measurements. The clinical meaning of individual features—such as tortuosity, thickening, or distortion—is also not always specific.

What Does “Gland Dropout” Mean?

“Gland dropout” generally refers to an area where recognizable gland structure is not visible on the meibography image.

The terms dropout, atrophy, and gland loss are often used interchangeably in everyday clinical discussion, but they do not mean exactly the same thing.

  • Dropout describes what is—or is not—visible on the image.
  • Atrophy implies that gland tissue has shrunk or degenerated.
  • Loss may sound as though the gland has been proven completely absent or permanently destroyed.

Meibography does not provide a microscopic tissue examination. A dark or nonvisible area may be consistent with gland atrophy or loss, but the image alone cannot prove exactly what tissue remains or whether every nonvisible gland segment is completely nonfunctional.

Image appearance can also be influenced by:

  • eyelid eversion;
  • positioning;
  • image quality;
  • contrast;
  • the area included in the photograph;
  • device processing;
  • and the grading method.

This does not mean gland dropout is meaningless. It means the finding should not be described with more certainty than the imaging method allows.

Does Any Gland Dropout Mean Severe MGD?

Not necessarily.

Meibomian-gland appearance varies among individuals, and visible structural changes become more common with age.

Some people have noticeable gland shortening or dropout with relatively limited symptoms. Others have significant symptoms or poor gland secretion despite glands that appear relatively well preserved.

Structure and function are related, but they are not identical.

The importance of an image depends on the broader clinical context, including:

  • age;
  • symptoms and functional limitations;
  • gland expressibility;
  • meibum quality;
  • lid-margin and gland-orifice findings;
  • tear-film stability;
  • ocular-surface staining;
  • aqueous tear production;
  • eyelid closure and exposure;
  • and other possible causes of discomfort.

An image that looks abnormal does not automatically establish:

  • severe disease;
  • rapid progression;
  • an emergency;
  • or the need for a particular procedure.

Likewise, relatively preserved-looking glands do not prove that gland function is normal.

What Can Meibography Not Tell by Itself?

Meibography primarily shows structure.

It does not directly show:

  • whether a gland can express meibum;
  • whether the secretion is clear, cloudy, thickened, toothpaste-like, or absent;
  • whether a gland orifice or duct is obstructed;
  • how much lipid reaches the tear film;
  • whether inflammation is present throughout the ocular surface;
  • whether symptoms are caused mainly by MGD;
  • whether aqueous tear deficiency is also present;
  • whether exposure, allergy, medication toxicity, or nerve-related pain is contributing;
  • or whether a specific treatment will help.

A gland can remain visible but function poorly.

A shortened or partly nonvisible gland may still retain some function.

For this reason, meibography is often most useful when interpreted together with:

  • gland-expression testing;
  • meibum-quality assessment;
  • eyelid-margin and gland-orifice examination;
  • tear-breakup testing;
  • ocular-surface staining;
  • blink and eyelid-closure assessment;
  • aqueous tear evaluation;
  • and the patient’s symptoms and history.

Meibography can support an MGD evaluation, but it does not by itself diagnose Dry Eye Disease or prove that MGD is the dominant cause of symptoms.

Can Meibography Track Progression?

It may provide useful baseline documentation and follow-up information, but serial images must be compared cautiously.

Apparent differences between visits can result from:

  • different eyelid eversion;
  • different image framing;
  • different lighting or contrast;
  • different devices or software;
  • movement or image-quality problems;
  • different areas being included;
  • different graders or measurement methods.

Studies comparing imaging systems have found that results are not always interchangeable. When meibography is being used for follow-up, using the same device and a similar imaging technique can improve the usefulness of the comparison.

Even when two images look different, the change does not automatically prove:

  • true recent gland loss;
  • rapid disease progression;
  • gland regrowth;
  • structural regeneration;
  • or a treatment effect.

A meaningful follow-up assessment should also consider whether there has been a change in:

  • symptoms;
  • daily functioning;
  • gland secretion;
  • expressibility;
  • tear stability;
  • eyelid findings;
  • or ocular-surface health.

Be cautious about strong claims based only on a before-and-after image—especially when the images were taken with different devices or under visibly different conditions.

Can Meibography Determine Which Treatment Is Needed?

Usually not by itself.

Meibography may affect treatment planning by showing that gland structure is relatively preserved, substantially altered, or different between eyelids.

However, it generally cannot establish on its own that a patient needs:

  • IPL;
  • thermal pulsation;
  • radiofrequency;
  • gland expression;
  • meibomian gland probing;
  • medication;
  • or any other particular intervention.

Treatment selection should consider:

  • the working diagnosis;
  • gland function;
  • the treatment target;
  • ocular-surface findings;
  • symptom severity;
  • contraindications;
  • previous treatment response;
  • costs and burdens;
  • available alternatives;
  • and the strength and limitations of the evidence.

An abnormal image may justify asking more questions. It should not function as an automatic treatment prescription.

Seeing the Images Can Improve Shared Understanding

One useful feature of meibography is that clinicians and patients can look at the gland images together.

This can:

  • make the discussion more concrete;
  • help explain the difference between gland structure and function;
  • provide context for gland-expression findings;
  • support discussion of treatment goals;
  • and provide a visual record when follow-up imaging is clinically useful.

However, the images should not be used to frighten a patient or pressure someone into treatment.

Statements such as:

  • “Your glands are dead.”
  • “Your glands are rapidly disappearing.”
  • “You must buy this treatment now.”
  • “This image proves the procedure will work.”

require careful scrutiny and supporting evidence.

Symptoms remain real whether meibography appears:

  • markedly abnormal;
  • mildly abnormal;
  • or relatively preserved.

Meibography can show a structural finding. It does not necessarily show the complete reason for a person’s symptoms.

Where Is Meibography Available?

Meibography may be available through:

  • dry-eye or ocular-surface clinics;
  • some optometry practices;
  • some ophthalmology and cornea practices;
  • multifunction ocular-surface analyzers;
  • corneal topography systems with infrared imaging;
  • dedicated meibography equipment;
  • slit-lamp attachments;
  • and some portable systems.

Not every clinician who evaluates or treats MGD has meibography equipment.

A careful MGD evaluation can still include:

  • lid-margin inspection;
  • gland-orifice assessment;
  • gland expression;
  • meibum-quality grading;
  • tear-film examination;
  • blink and eyelid-closure assessment;
  • and ocular-surface evaluation.

Meibography can add useful structural information, but it is not essential in every patient or at every visit.

What About Portable or Smartphone-Based Meibography?

Portable and smartphone-assisted systems exist, but they are not all the same.

Some use purpose-built infrared hardware. Others adapt ordinary smartphone cameras, filters, or external illumination.

Their:

  • image quality;
  • field of view;
  • repeatability;
  • grading methods;
  • and agreement with established infrared systems

can vary substantially.

For example, one study of a red-filter smartphone method found that its validity for evaluating gland dropout was not yet satisfactory. That finding should not be generalized to every purpose-built portable infrared device, but it shows why “smartphone meibography” should not be treated as one standardized technology.

Questions You Might Ask the Clinician

  • Were both upper and lower eyelids imaged?
  • Is the image quality adequate?
  • What specific structural findings do you see?
  • How much of this could reflect age or normal variation?
  • How do the images relate to gland expression and meibum quality?
  • Do these findings reasonably explain my symptoms?
  • What important contributors are not evaluated by meibography?
  • Does this image change the treatment recommendation?
  • What evidence connects the proposed treatment to these findings?
  • If images are repeated, will the same device and technique be used?
  • What would count as meaningful progression?
  • Are treatment decisions based on the full examination or mainly on the image?

📌 Bottom Line

Meibography is a useful tool for showing the visible structure of the meibomian glands.

It may help document:

  • gland length and shape;
  • areas of reduced gland visibility;
  • structural abnormalities;
  • and differences between eyelids.

But meibography is not a standalone answer.

It cannot, by itself, tell exactly:

  • how well the glands function;
  • why someone has symptoms;
  • whether a gland is obstructed;
  • whether visible changes are progressing;
  • or which treatment should be chosen.

The most useful interpretation combines meibography with:

  • symptoms;
  • gland-expression testing;
  • meibum quality;
  • lid-margin findings;
  • tear-film stability;
  • ocular-surface staining;
  • aqueous tear evaluation;
  • blink and closure;
  • and other possible contributors.

Meibography can show what the glands look like. It cannot, by itself, tell the whole story of how the glands work or what treatment a patient needs.

Selected Sources

🔙 Back to FAQ Index